Delcath Systems’ (NSDQ:DCTH) agreement with the European Institute of Oncology will launch European commercialization for the New York-based company’s Chemostat organ-targeting chemotherapy system.
Under the terms of the deal, Delcath will provide the Milan, Italy-based cancer center with logistics and clinical training support for the Chemostat system, which is awaiting full CE Mark approval.
The Chemostat device uses a system of tubes to localize the delivery of toxic chemotherapy agents by isolating the targeted organ from the rest of the body’s bloodstream. It won CE Mark approval for the a liver cancer indication in April.
"After years of clinical research and development, Chemostat will soon be available to patients," Eamonn Hobbs, Delcath president & CEO said in prepared remarks. "We’re pleased that our first launch and training agreement is with such a prestigious institution as the IEO, one of Europe’s premier cancer treatment and research facilities."
Systagenix inks German distribution deal
Systagenix Wound Management teamed up with TRIGOcare GmbH, previously a generic medical devices dealer, to distribute Systagenix products in Germany.
“Together Systagenix and TRIGOcare offer a complete assortment of wound care products to meet the needs of any care model in every price segment,” according to a press release.
McKesson GPO inks deal with Bio-Reference Labs
Bio-Reference Laboratories Inc. (NSDQ: BRLI) landed a purchasing agreement with McKesson Specialty Health group purchasing organization, the Onmark GPO.
The agreement gives Onmark’s nationwide system of community-based practices access to Bio-Reference’s clinical diagnostic services.
Hospital GPOs have been signing a flurry of deals recently, perhaps in response to Medtronic’s (NYSE:MDT) headline-making, Wall-Street-pleasing decision to cut several contracts worth an estimated $2 billion annually.